seladelpar in patients with primary biliary cholangitis and compensated cirrhosis efficacy and safety from response and assure studies

Original title: “Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.”

fracture risk under selective and non selective ppar agonists in primary biliary cholangitis

Original title: “Fracture risk under selective and non-selective PPAR agonists in primary biliary cholangitis.”

meta analysis ppar agonists for pruritus and quality of life in primary biliary cholangitis

Original title: “Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.”

primary biliary cholangitis and prognostic models reply

Original title: “Primary Biliary Cholangitis and Prognostic Models-Reply.”

bullous pemphigoid and primary biliary cholangitis a rare association with therapeutic challenge

Original title: “[Bullous pemphigoid and primary biliary cholangitis, a rare association with therapeutic challenge].”

optimising primary therapy in primary biliary cholangitis opera protocol for a randomised double blind placebo controlled trial of enhanced primary therapy with obeticholic acid

Original title: “Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.”

metabolic syndrome and its individual components but not masld are associated with advanced fibrosis in primary biliary cholangitis

Original title: “Metabolic syndrome and its individual components but not MASLD are associated with advanced fibrosis in primary biliary cholangitis.”

pbc ireland patient registry study protocol for a national platform on primary biliary cholangitis

Original title: “The PBC Ireland patient registry: study protocol for a national platform on primary biliary cholangitis.”

Nature Reviews Gastroenterology & Hepatology - The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view Greater transplant-free survival in patients receiving obeticholic acid for primary biliary cholangitis in a clinical trial setting compared to real-world external controls. Gastroenterology 163, 1630–1642.e3 (2022). ... Jones, D. E. J. et al. Primary biliary cholangitis drug evaluation and regulatory approval: where do we go from here? Hepatology 80, 1291–1300 (2024). ... Martins, A. et al. Comparative effectiveness of peroxisome proliferator–activated receptor agonists as second-line therapies for primary biliary cholangitis: a systematic review and network meta-analysis. Toronto Center for Liver Disease, University Health Network, Toronto, Ontario, Canada · Bettina E. Hansen · The Autoimmune and Rare Liver Disease Programme, Division of Gastroenterology and Hepatology, University Health Network, Toronto General Hospital, Toronto, Ontario, Canada The authors are all either officers or medical advisors to the PBC Foundation. All the authors other than R.M.-T. (who is a patient representative) are clinicians who are experienced investigators and have contributed to the development of licensed therapies in PBC. Table 1 Characteristics of the licensed and unlicensed second-line therapies currently used in primary biliary cholangitis ... Instant access to the full article PDF. ... Corpechot, C. et al. Bezafibrate for primary biliary cholangitis: time to act on the evidence. Nat. Rev. Gastroenterol. Hepatol. 22, 805–807 (2025). ... Corpechot, C. et al. A placebo-controlled trial of bezafibrate in primary biliary cholangitis.

Original title: “The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view | Nature Reviews Gastroenterology & Hepatology”

reply to the ethics of unlicensed therapy use in primary biliary cholangitis a counter view

Original title: “Reply to 'The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view'.”

ethics of unlicensed therapy use in primary biliary cholangitis a counter view

Original title: “The ethics of unlicensed therapy use in primary biliary cholangitis: a counter view.”

selective ppar activation and seladelpar efficacy in primary biliary cholangitis and beyond

Original title: “Selective PPAR δ Activation and Seladelpar Efficacy in Primary Biliary Cholangitis and beyond.”